Dulac Edward J III

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
13
Insider Sells Sum
$2.87M

Insider Activity of Dulac Edward J III

According to the SEC Form 4 filings, Dulac Edward J III, being in a position of

  1. Chief Financial Officer at Fate Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 16506 shares for $77,937,
    over all time since 2021-08-19, has bought 0 shares, and sold 80706 shares for $2.87M.

The largest sale of all time was on 2021-09-28 and amounted to 19460 shares of Fate Therapeutics, Inc. for $1.22M.

Biography of Dulac Edward J III

No biography is available at this moment.

2024-03-04SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
2,447
0.0027%
$7.77$19,013-46.89%
2024-01-29SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
1,849
0.0017%
$5.00$9,245-31.38%
2024-01-09SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
7,028
0.0071%
$4.37$30,712-11.33%
2024-01-02SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
5,182
0.0052%
$3.66$18,966+6.68%
2023-12-18SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
1,585
0.0018%
$3.50$5,548+22.91%
2023-08-18SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
4,718
0.0048%
$2.80$13,210+35.25%
2023-07-05SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
5,182
0.0053%
$4.83$25,029-22.74%
2023-01-10SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
7,331
0.0071%
$5.24$38,414-13.57%
2022-08-18SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
4,703
0.0048%
$29.75$139,914-80.03%
2022-01-11SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
1,770
0.0019%
$48.45$85,757-43.63%
2021-12-20SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
15,977
0.0168%
$60.00$958,620-51.66%
2021-09-28SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
19,460
0.021%
$62.53$1.22M-42.11%
2021-08-19SaleFate Therapeutics, Inc.
FATE
Chief Financial Officer
3,474
0.0038%
$88.26$306,602-55.38%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.